| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 15. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | vonicog alfa (Veyvondi®) |
| Formulation | 650 IU and 1300 IU powder and solvent for solution for injection |
| Reference number | 2956 |
| Indication | In adults (age 18 and older) with von Willebrand disease, when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the: treatment of haemorrhage and surgical bleeding; prevention of surgical bleeding |
| Company | Shire Pharmaceuticals Ltd |
| BNF chapter | Anaesthesia |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 18/04/2019 |